AChE antibody
- Known as:
- AChE (anti-)
- Catalog number:
- 10-1882
- Product Quantity:
- 200 ul
- Category:
- -
- Supplier:
- Fitzgerald
- Gene target:
- AChE antibody
Related genes to: AChE antibody
- Gene:
- ACHE NIH gene
- Name:
- acetylcholinesterase (Cartwright blood group)
- Previous symbol:
- YT
- Synonyms:
- -
- Chromosome:
- 7q22.1
- Locus Type:
- gene with protein product
- Date approved:
- 1989-06-02
- Date modifiied:
- 2019-04-23
Related products to: AChE antibody
Related articles to: AChE antibody
- Anticipatory prescribing is the prescribing and provision of medicines ahead of time to people whose death is expected. It is recognised as effective practice for patients receiving palliative and end of life care. The main aim of anticipatory prescribing is to ensure medicines are readily available to manage the symptoms that commonly occur at the end of life - such as pain, agitation, breathlessness, nausea and vomiting, and excess respiratory secretions. It also aims to prevent unwanted hospital admission if the patient's chosen place of death is at home. This article explores the evidence and guidance to support anticipatory prescribing, alongside the benefits and challenges associated with this practice. - Source: PubMed
Publication date: 2026/08/17
Edwards Barbara - Pudendal nerve entrapment (PNE) within Alcock's canal is an under-recognized cause of chronic pelvic and perineal pain, increasingly conceptualized as a compartment-like syndrome due to sustained neurovascular compression within a confined fascial space. This systematic review evaluates the anatomical, pathophysiological, diagnostic, and therapeutic evidence supporting this hypothesis. A comprehensive literature search was conducted across PubMed, Embase, Scopus, and the Cochrane Library from April 2026 to May 1, 2026, in accordance with Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines. Ten studies were included in the final synthesis, comprising observational studies, cadaveric anatomical analyses, imaging-based diagnostic studies, and interventional and surgical outcome studies. Sample sizes ranged from a cadaveric series of 15-20 specimens to clinical cohorts exceeding 200 patients. Evidence consistently demonstrated that repetitive mechanical stress, fascial constriction, and impaired venous drainage within Alcock's canal may lead to ischemic neuropathy and progressive pudendal dysfunction. Diagnostic modalities such as magnetic resonance (MR) neurography, Nantes criteria, and nerve blocks improved clinical identification, while surgical decompression showed variable but often favorable outcomes. However, significant heterogeneity, small sample sizes, and a lack of standardized outcome measures limit definitive conclusions. Overall, current evidence supports a compartment-like pathophysiology, although further prospective validation is required. - Source: PubMed
Publication date: 2026/07/17
Okoye JideoforHamid Mohammed Moazer IbrahimSubhedar DivyankAbdalla Mohamed Mohamed IshaqShetty ShashwatAli Rizwan - Introduction Liposomal bupivacaine (LB) produces a prolonged serum bupivacaine level. It carries a warning to avoid additional local anesthetics for 96 hours due to a theoretical additive risk of local anesthetic systemic toxicity (LAST). Whether patients exposed to additional local anesthetics soon after LB have a clinically detectable increased risk of LAST is unknown. Materials and methods Data from a single academic center were used in a cohort study of adults who received LB intraoperatively. The exposure was to additional local anesthetics within 96 hours of LB administration, and the outcome was a composite of electronic medical record data indicating possible LAST. The cumulative incidence and hazard of possible LAST (with weighted adjustment for propensity to exposure to additional local anesthetics) were calculated. A propensity score-matched sensitivity analysis was performed using an outcome based on a manual chart review. Results We identified 4306 patients who received LB, of whom 466 (12.1%) were exposed to additional local anesthetics within 96 hours of LB. There was no significant difference in the cumulative incidence of possible LAST between exposed and unexposed patients (0.9% vs. 1.5%, p = 0.28) as compared to unexposed and no significant increase in the unadjusted hazard (HR 0.51, 95% CI 0.18-1.42, p = 0.21) or the adjusted hazard (HR 0.25, 95% CI 0.07-0.89, p = 0.033) of possible LAST after exposure to additional local anesthetic. The sensitivity analysis had similar findings. Conclusions We found no evidence that exposure to additional local anesthetics within 96 hours of LB administration increases the hazard of possible LAST. - Source: PubMed
Publication date: 2026/07/17
Veloria DaniellaXu LeiRader ElizabethHa DavidGessner Daniel - Although follow-up is recommended for 2 years after lumbar spinal stenosis (LSS) surgery, some patients fail to complete all follow-up visits. In recent years, the treatment burden on older adults has attracted increasing attention, with particular emphasis on outpatient visits. Thus, we aimed to clarify the clinical characteristics of older adults who discontinued postoperative follow-up between 1 and 2 years after LSS surgery. - Source: PubMed
Publication date: 2026/02/16
Imai TakayaMichikawa TakehiroKawabata SoyaAkaike YukiNagai SotaTakeda HirokiIkeda DaikiKaneko ShinjiroFujita Nobuyuki - Anterior sacroiliac joint (SIJ) fusion has been performed for severe SIJ disorders and has demonstrated stable long-term outcomes; however, its relatively high invasiveness remains a significant concern. To overcome this limitation, we developed a posterior fusion using transarticular cylindrical cages combined with posterior instrumentation. This study describes the posterior SIJ fusion technique and evaluates the surgical outcomes. - Source: PubMed
Publication date: 2026/04/08
Kurosawa DaisukeMurakami EiichiSasaki TakeshiOzawa Hiroshi